Business & Startups

Business

Vercel Doubles Down on AI Infrastructure with SDK 7

Vercel just rolled out AI SDK 7, complete with zero-overhead execution loops and unified telemetry—basically a digital wizard’s hat that automates the boring bits of AI deployment while promising to keep your spells from catching fire. They’re doubling down as the frontend deity for the AI gold rush, which is great if you like your infrastructure served with a side of corporate lock-in. Because nothing says “democratizing the future” quite like a single company becoming the default landlord for every AI-powered widget the web can dream up.

The new stream and tool orchestration is all about making your AI feel less like a clunky chatbot and more like a smoothly integrated co-conspirator. But let’s not kid ourselves: “unified telemetry” is the tech equivalent of an all-seeing eye with a friendly user interface. It’s like giving your landlord a master key and a security camera subscription, then calling it “developer experience.” Sure, zero-overhead loops sound fast and sexy, but underneath that slick hood is the same old playbook: centralize the data, control the pipeline, and call it innovation while the surveillance creepers sharpen their teeth.

Vercel’s SDK 7 is a powerful incantation, no doubt, but it’s worth asking who holds the grimoire. Every new AI tool from a major platform is a trade-off between velocity and autonomy—and, increasingly, between utility and the quiet erasure of user agency. The real story here isn’t how fast we can run a loop; it’s whether we’re building a digital commons or a gilded cage. As developers, we get to choose what we optimize for. So go ahead, wave your wand—but maybe keep a backup plan in your other pocket.

Business

Liquid AI Ships Compact Non-Transformer Model

In the AI world, everyone’s been worshipping at the altar of the transformer—the gargantuan, energy-sucking neural architecture that requires more GPUs than a crypto bro’s wet dream. But Liquid AI just walked in with a flask of something called LFM 2.5, a non-transformer model that packs 230 million parameters and punches above its weight class, matching models three times its size. It’s like discovering that the scrappy indie band from your local dive bar plays better than the stadium-filling auto-tuned pop stars—and does it on a fraction of the electricity.

This matters because the current AI gold rush is built on corporate server farms that guzzle water and power while hoarding your data in the cloud. Liquid AI is targeting edge computing—meaning your phone, your car, your smart toothbrush could run serious AI without phoning home to Bezos or Zuckerberg. That’s a win for privacy, a win for the climate, and a middle finger to the surveillance capitalism playbook. It’s not just clever engineering; it’s a political statement about who controls the intelligence that runs our devices.

So while Silicon Valley keeps pushing bigger, dumber models, Liquid AI is proving that small is beautiful—and that we don’t need to burn the planet to get smart assistants that actually listen. The real revolution isn’t another trillion-parameter beast; it’s the chips and algorithms that let you keep your data local. As we march toward a future of ubiquitous AI, let’s remember: the most powerful technology is the one you can switch off. Or, barring that, the one that doesn’t require a data center the size of a Costco to run. Stay sharp, keep your cookies private, and never trust a model that needs a nuclear reactor.

Business

TLDR Is Hiring a Curator for TLDR Hardware

Sure, here's the post:

Stop the presses—or, more accurately, stop the infinite RSS feed of your brain. TLDR is hiring a curator for a shiny new hardware newsletter, and they’ve already got 500,000 pre-signups. That’s half a million people who’ve decided they’d rather have a digest of chip specs and robot gossip than, say, touch grass. It’s a smart play: the space was a desert of dry press releases, and now they’re promising an oasis. But let’s be real—this isn’t just about convenient curation. It’s about owning the pipeline of attention in an industry increasingly dominated by the kind of tech that tracks what you eat, where you sleep, and who you call your “emotional support human.” Congrats, TLDR, you’re now the algorithmic gatekeeper for the hardware that’s quietly turning our world into a giant Panopticon.

Let’s talk about what “hardware” actually means in 2025: chips for facial recognition that police use to harass Black teenagers, robotics that replace union jobs at Amazon warehouses, and energy infrastructure that Bill Gates is betting will save us from climate collapse—if we let his nuclear startup profit off the rubble first. This newsletter will inevitably celebrate breakthroughs while carefully ignoring who gets crushed in the process. It’s like building a shrine to the Golden Gate Bridge while forgetting the people who fell into the concrete. TLDR gets to brand itself as the sharp-witted insider, but without a critical lens, they’re just a glossy catalog for the surveillance state. You can almost hear the Venture Capital bros chugging Soylent as they refresh the subscription page.

Here’s the thing: I want this to be good. I want a hardware digest that calls out Tesla’s self-driving deaths, questions who owns the patents on next-gen battery tech, and has the guts to say that more drones are not going to fix a broken society. But if TLDR plays it safe, this will be another velvet rope into a club where the bouncer is an algorithm and the drink special is “disruption.” The question isn’t whether 500,000 people want to know what’s new—it’s whether they’ll be told who’s really pulling the levers. And right now, I’m not holding my breath. I’m just watching the chips fall.

Business

Sanofi Under EU Antitrust Probe

So Sanofi, the French pharma giant, is getting a stern knock on the door from EU antitrust regulators for allegedly bad-mouthing a rival’s flu shot like a high school mean girl who peaked at the vaccine symposium. The accusation? Conducting a not-so-subtle smear campaign against a competitor’s product to protect its own market share. It’s the corporate equivalent of slashing tires in the parking lot, except these tires help prevent the seasonal plague. This probe should remind us that in the high-stakes world of public health, the line between “competitive intelligence” and “dangerous disinformation” is thinner than a single-payer advocate’s patience with profiteering.

Here’s the thing about flu vaccines: they’re not luxury handbags. When a company like Sanofi disparages a rival jab to gain an edge, they’re not just playing hardball—they’re potentially fueling vaccine hesitancy for the sake of a bonus. And this isn’t just a “both sides do it” scenario. The progressive take is clear: when a market with massive public health implications is dominated by a few giants, the incentive to crush competition outweighs the incentive to, you know, keep people healthy. This is the same logic that lets polluters lobby to weaken emissions rules and lets tech platforms surveil you for ad revenue. Power without accountability is a feature, not a bug, of late-stage capitalism.

What sticks with me is the reminder that antitrust enforcement isn’t just about protecting consumers from price gouging—it’s about safeguarding the very integrity of our public goods. If the EU finds Sanofi guilty, we might finally see regulators treat health misinformation as a form of market abuse, not just a Twitter policy problem. Until then, remember: when a pharma executive starts talking about “science,” check which patent they’re trying to protect. In a world of pandemics and superbugs, we can’t afford a playground where one bully gets to rewrite the rules.

Business

STAT+: European antitrust regulators probe Sanofi for allegedly disparaging a rival flu vaccine

So it turns out Sanofi — the pharmaceutical giant that brought us the flu shot you pretend to get every year — has been playing dirty in the European vaccine sandbox. Regulators are now probing whether Sanofi tried to sabotage a rival’s flu vaccine by spreading misleading claims. Not a bad business strategy if you can get away with it: if you can’t out-innovate, just out-smear. It’s the corporate equivalent of tripping the faster kid in a race, then complaining about their running form.

Let’s be clear: this isn’t some minor, “both sides have a point” kerfuffle. This is about market dominance being protected through distortion, not competition. Big Pharma already holds the patent keys to the kingdom; when they start gaslighting patients and doctors about a competitor’s product, it’s not capitalism — it’s a schoolyard chokehold on public health. And it’s especially rich given that we’re in a global moment where trust in vaccines is already more fragile than a glass syringe.

Sanofi’s alleged tactic is a reminder that regulatory bodies like the EU’s antitrust arm aren’t just bureaucratic paper-pushers — they’re the last line of defense against a system where the biggest checkbook writes the narrative. The real question isn’t whether Sanofi will get a slap on the wrist, but whether this probe will force the industry to remember that a vaccine’s worth shouldn’t be determined by a corporate PR budget. Because if your flu shot can’t stand on its own merits, maybe the only virus worth worrying about is your own greed.